The ATAC adjuvant breast-cancer trial: Six-year results of the endometrial subprotocol

References

• ATAC Trialists' Group. 2002. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359:2131–2139.
   PubMed Web of Science ®Google Scholar
• ATAC Trialists' Group. 2005. Results of the ATAC (Arimidex, Tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365:60–62.
   PubMed Web of Science ®Google Scholar
• ATAC Trialists' Group. 2006. Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. Lancet Oncology 7:633–643.
   PubMed Web of Science ®Google Scholar
• Bergman L, Beelen ML, Gallee MP, Hollema H, Benraadt J, van Leeuwen FE. 2000. Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres' ALERT Group. Assessment of Liver and Endometrial Cancer Risk following Tamoxifen. Lancet 356:881–887.
   PubMed Web of Science ®Google Scholar
• Bonneterre J, Buzdar A, Nabholtz JM, Robertson JF, Thürlimann B, von Euler M et al 2001. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer 92:2247–2258.
   PubMed Web of Science ®Google Scholar
• Buttram VC Jr. 1986. Uterine leiomyomata – aetiology, symptomatology and management. Progress in Clinical and Biological Research 225:275–296.
   PubMedGoogle Scholar
• Buzdar AU. 2005. Aromatase inhibitors: changing the face of endocrine therapy for breast cancer. Breast Disease 24:107–117.
   PubMedGoogle Scholar
• Coates AS, Keshaviah A, Thurlimann B, Mouridsen H, Mauriac L, Forbes JF et al 2007. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1–98. Journal of Clinical Oncology 25:486–492.
   PubMed Web of Science ®Google Scholar
• Decensi A, Fontana V, Bruno S, Gustavino C, Gatteschi B, Costa A. 1996. Effect of tamoxifen on endometrial proliferation. Journal of Clinical Oncology 14:434–440.
   PubMed Web of Science ®Google Scholar
• Duffy S, Distler W, on behalf of the ATAC Trialists' Group. 2005. Gynecological interventions during adjuvant therapy with anastrozole or tamoxifen: Results from the ATAC trial. Poster 2056 presented at the San Antonio Breast Cancer Symposium.
   Google Scholar
• Duffy S, Jackson TL, Lansdown M, Philips K, Wells M, Pollard S et al 2006. The ATAC (‘Arimidex’, Tamoxifen, Alone or in Combination) adjuvant breast cancer trial: first results of the endometrial sub-protocol following 2 years of treatment. Human Reproduction 21:545–553.
   PubMed Web of Science ®Google Scholar
• Duffy S, Jackson TL, Lansdown M, Philips K, Wells M, Pollard S et al 2003. The ATAC adjuvant breast cancer trial in postmenopausal women: baseline endometrial subprotocol data. BJOG: an International Journal of Obstetrics and Gynaecology 110:1099–1106.
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists' Collaborative Group. 1998. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351:1451–1467.
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists' Collaborative Group. 2004. Tamoxifen for early breast cancer (Cochrane Review). In: The Cochrane Library. 1st ed. Chichester: John Wiley and Sons, Ltd. p 1–38.
   Google Scholar
• Early Breast Cancer Trialists' Collaborative Group. 2005. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687–1717.
   PubMed Web of Science ®Google Scholar
• Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM et al 1998. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. Journal of the National Cancer Institute 90:1371–1388.
   PubMed Web of Science ®Google Scholar
• Fisher B, Dignam J, Bryant J, DeCillis A, Wickerham DL, Wolmark N et al 1996. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. Journal of the National Cancer Institute 88:1529–1542.
   PubMed Web of Science ®Google Scholar
• Houghton J, on behalf of the ATAC Trialists' Group. 2006. Initialadjuvant therapy with anastrozole reduces rates of early breast cancer recurrence and adverse events compared with tamoxifen – data reported on behalf of the ATAC trialists group. Poster 243 presented at the ESMO, 29 Sept-3 Oct.
   Google Scholar
• Markovitch O, Tepper R, Fishman A, Aviram R, Cohen I. 2009. Long-term ‘protective’ effect of aromatase inhibitors on the endometrium of postmenopausal breast cancer patients. Breast Cancer Research and Treatment 113:321–326.
   PubMed Web of Science ®Google Scholar
• Mazur MT, Kurman RJ. 2005. Diagnosis of endometrial biopsies and curettings: a practical approach. 2nd ed. New York: Springer.
   Google Scholar
• Miller WR. 1999. Biology of aromatase inhibitors: pharmacology/endocrinology within the breast. Endocrine-related Cancer 6:187–195.
   PubMed Web of Science ®Google Scholar
• Nabholtz JM, Bonneterre J, Buzdar A, Robertson JFR, Thürlimann B, for the Arimidex Writing Committee on behalf of the Investigators 2003. Anastrozole (Arimidex™) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results. European Journal of Cancer 39:1684–1689.
   PubMed Web of Science ®Google Scholar
• Nabholtz JM, Buzdar A, Pollak M, Harwin W, Burton G, Mangalik A et al 2000. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. Journal of Clinical Oncology 18:3758–3767.
   PubMed Web of Science ®Google Scholar
• Schiff R, Massarweh SA, Shou J, Bharwani L, Mohsin SK, Osborne CK. 2004. Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance. Clinical Cancer Research 10:331S–336S.
   PubMed Web of Science ®Google Scholar
• Shou J, Massarweh S, Osborne CK, Wakeling AE, Ali S, Weiss H et al 2004. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. Journal of the National Cancer Institute 96:926–935.
   PubMed Web of Science ®Google Scholar
• Wickerham DL, Fisher B, Wolmark N, Bryant J, Costantino J, Bernstein L et al 2002. Association of tamoxifen and uterine sarcoma. Journal of Clinical Oncology 20:2758–2760.
   PubMed Web of Science ®Google Scholar